Search results for "Hypertensive"

showing 10 items of 250 documents

The metabolic syndrome in hypertension: European society of hypertension position statement.

2008

The metabolic syndrome considerably increases the risk of cardiovascular and renal events in hypertension. It has been associated with a wide range of classical and new cardiovascular risk factors as well as with early signs of subclinical cardiovascular and renal damage. Obesity and insulin resistance, beside a constellation of independent factors, which include molecules of hepatic, vascular, and immunologic origin with proinflammatory properties, have been implicated in the pathogenesis. The close relationships among the different components of the syndrome and their associated disturbances make it difficult to understand what the underlying causes and consequences are. At each of these …

medicine.medical_specialtyPhysiologySodium Chloride Symporter InhibitorsAdrenergic beta-AntagonistsPhysical exerciseAngiotensin-Converting Enzyme InhibitorsType 2 diabetesBioinformaticsInsulin resistanceWeight lossInternal medicineInternal MedicinemedicineHumansThiazideAntihypertensive AgentsMetabolic Syndromebusiness.industrymedicine.diseaseCalcium Channel BlockersObesityExercise TherapyEndocrinologyBlood pressureHypertensionmedicine.symptomMetabolic syndromeCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor BlockersRisk Reduction Behaviormedicine.drugDiet TherapyJournal of hypertension
researchProduct

Practical solutions to the challenges of uncontrolled hypertension: a white paper.

2008

This white paper is an urgent call to action from aninternational group of physicians. The continued failure tocontrolhypertensiontakesanunacceptabletollon patients,families and society and it must be addressed. Any patientwith blood pressure of 140/90 mmHg or greater can becharacterizedasa ‘challengingpatient’,is atsignificant risk,and requires persistent optimization of therapy until targetblood pressure is achieved. Six key challenges in reachingthis goal blood pressure are described: (1) inadequateprimary prevention; (2) faulty awareness of risk; (3) lack ofsimplicity; (4) therapeutic inertia; (5) insufficient patientempowerment; and (6) unsupportive healthcare systems.This white paper id…

medicine.medical_specialtyPhysiologybusiness.industryCall to actionWhite paperBlood pressureHealth careHypertensionInternal MedicinemedicineHumansCardiology and Cardiovascular MedicineIntensive care medicinebusinessAntihypertensive AgentsNeeds AssessmentJournal of hypertension. Supplement : official journal of the International Society of Hypertension
researchProduct

Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias an…

2012

Hypertension is the most common cardiovascular disorder and atrial fibrillation is the most common clinically significant arrhythmia. Both these conditions frequently coexist and their prevalence increases rapidly with aging. There are different risk factors and clinical conditions predisposing to the development of atrial fibrillation, but due its high prevalence, hypertension is still the main risk factor for the development of atrial fibrillation. Several pathophysiologic mechanisms (such as structural changes, neurohormonal activation, fibrosis, atherosclerosis, etc.) have been advocated to explain the onset of atrial fibrillation. The presence of atrial fibrillation per se increases th…

medicine.medical_specialtyPhysiologymacromolecular substancesFibrosisRisk FactorsCardiovascular DisorderInternal medicineThromboembolismAtrial FibrillationInternal MedicinemedicineHumanscardiovascular diseasesRisk factorStrokeSocieties Medicalbusiness.industryWarfarinAtrial fibrillationHypertension atrial fibrillation anticoagulants antihypertensive treatmentMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREmedicine.diseaseThrombosisEuropeBlood pressureHypertensionCardiologyCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct

Renal protection by antihypertensive drugs

1998

During the last few years there has been a renewed interest in blood-pressure (BP)-induced kidney damage, owing to a progressive increase in the incidence and prevalence of hypertension and vascular diseases as a cause of end-stage renal disease (ESRD). The need to prevent ESRD demands continued efforts so as to identify early those people with hypertension who are at risk and to provide them with effective antihypertensive therapy. This review analyses what is needed in terms of surrogate endpoints for monitoring kidney damage and what is known about the impact of antihypertensive treatments in reducing the BP burden on the kidney in non-diabetic subjects. Although glomerular filtration ra…

medicine.medical_specialtyPhysiologymedicine.drug_classRenal functionBlood PressureKidneyurologic and male genital diseasesEssential hypertensionNephropathyRisk FactorsInternal medicineInternal MedicinemedicineAlbuminuriaHumansAntihypertensive drugAntihypertensive AgentsKidneyProteinuriabusiness.industrySurrogate endpointmedicine.diseasefemale genital diseases and pregnancy complicationsEndocrinologymedicine.anatomical_structureHypertensionCardiologyKidney Failure ChronicMicroalbuminuriamedicine.symptomCardiology and Cardiovascular MedicinebusinessJournal of Hypertension
researchProduct

Electrocardiography for Assessment of Hypertensive Heart Disease: A New Role for an Old Tool

2016

Left ventricular (LV) hypertrophy (LVH), detected either by electrocardiography (ECG) or echocardiography (ECHO), has long been recognized as a powerful predictor of serious cardiovascular (CV) sequelae. A very large and highly consistent body of evidence indicates that LVH is not only an adaptation to increased hemodynamic load in hypertension, but is also independently associated with an enhanced risk for myocardial infarction, cardiac sudden death, congestive heart failure, and stroke in the general population, as well as in patients with systemic hypertension, coronary heart disease, chronic kidney disease, and atrial fibrillation. Intriguingly, the cumulative incidence of cardiovascula…

medicine.medical_specialtySettore MED/09 - Medicina InternaCardiology and Cardiovascular Medicine; Internal Medicine; Endocrinology Diabetes and MetabolismEndocrinology Diabetes and MetabolismPopulation030204 cardiovascular system & hematologyCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineMedicinecardiovascular diseases030212 general & internal medicineMyocardial infarctioneducationSettore MED/14 - Nefrologiaeducation.field_of_studymedicine.diagnostic_testbusiness.industryAtrial fibrillationmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareHypertensive heart diseaseBlood pressureHeart failureCardiologyPhysical therapyCardiology and Cardiovascular MedicinebusinessElectrocardiography
researchProduct

European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the second international consensus conference …

2008

This document summarizes the available evidence and provides recommendations on the use of home blood pressure monitoring in clinical practice and in research. It updates the previous recommendations on the same topic issued in year 2000. The main topics addressed include the methodology of home blood pressure monitoring, its diagnostic and therapeutic thresholds, its clinical applications in hypertension, with specific reference to special populations, and its applications in research. The final section deals with the problems related to the implementation of these recommendations in clinical practice. ispartof: Journal of Hypertension vol:26 issue:8 pages:1505-1530 ispartof: location:Neth…

medicine.medical_specialtySpecial populationsPhysiologybusiness.industryMEDLINEConsensus conferenceMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring Ambulatoryguidelinesarterial hypertension cardiovascular risk home blood pressure monitoringClinical PracticeEuropeHypertensionInternal MedicinemedicineHumansBlood pressure monitoringHypertension diagnosisDrug MonitoringCardiology and Cardiovascular MedicineIntensive care medicinebusinessAntihypertensive Agents
researchProduct

European Society of Hypertension Working Group on Obesity: background, aims and perspectives.

2007

Clinica Medica, University ofMilano-Bicocca, Ospedale San Gerardo, Monza, Milan, ItalyCorrespondence and requests for reprints to Professor Jens Jordan, ChairmanWorking Group on Obesity, Franz Volhard Clinical Research Center, HELIOSKlinikum Berlin and Medical Faculty of the Charite´, Wiltbergstrase 50, 13125Berlin, GermanyTel: +49 30 9417 2220; fax: +49 30 9417 2265; e-mail: jens.jordan@charite.de

medicine.medical_specialtySympathetic Nervous SystemPhysiologybusiness.industryNutritional statusBlood PressureBaroreflexWeight LoSurgeryEuropeAntihypertensive AgentFamily medicineHypertensionWeight LossInternal MedicineMedicineHumansObesityCardiology and Cardiovascular MedicinebusinessAntihypertensive AgentsSocieties MedicalJournal of hypertension
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct

Impact of Structural Heart Disease on the Acute Complication Rate in Atrial Fibrillation Ablation: Results from the German Ablation Registry

2013

Acute Complication Rate in AF Ablation Introduction Catheter ablation (CA) has emerged as a widespread therapeutic option in the treatment of atrial fibrillation (AF). Currently, no safety data with regard to the impact of the underlying structural heart diseases (SHD) are available. We sought to assess the risk for acute and long-term complications during CA of AF in relation to underlying SHD. Methods and Results We included 6,211 patients in a prospective registry undergoing CA of AF in 41 nationwide centers. All patients were divided into 4 groups according to the underlying heart disease: No SHD (69.4%), hypertensive heart disease (HHD) (12.0%), coronary artery disease (CAD) (15.1%), a…

medicine.medical_specialtyUnivariate analysisHeart diseasebusiness.industrymedicine.medical_treatmentCardiomyopathyAtrial fibrillationCatheter ablationOdds ratiomedicine.diseaseHypertensive heart diseaseCoronary artery diseasePhysiology (medical)Internal medicinemedicineCardiologyCardiology and Cardiovascular MedicinebusinessJournal of Cardiovascular Electrophysiology
researchProduct

In vivo angiotensin I-converting enzyme inhibition by long-term intake of antihypertensive lactoferrin hydrolysate in spontaneously hypertensive rats

2013

Abstract We evaluated the effect of the long-term intake of a bovine lactoferrin hydrolysate enriched in low molecular weight peptides (LFH  in vivo mechanism of action. Male spontaneously hypertensive rats received tap water (negative control), captopril (positive control, 76 mg/kg/day), LFH  in vivo mechanism for the antihypertensive effect of long-term oral administration of LFH

medicine.medical_specialtybiologyChemistryLactoferrinCaptoprilHydrolysateSpontaneously hypertensive ratEndocrinologyMechanism of actionOral administrationIn vivoInternal medicineRenin–angiotensin systemmedicinebiology.proteinmedicine.symptomFood Sciencemedicine.drugFood Research International
researchProduct